COVID-19 has raised the profile of violence against women and children (VAW/C) within the global discourse. Nine months after the emergence of COVID-19, global stakeholders continue to advocate for increased funding and action to mitigate against the risk of violence on vulnerable populations and support survivors. How much have we learned from research since the beginning of the crisis?
Sound Banks for Healthy Economies: Challenges for Policymakers in Latin America and the Caribbean in Times of Coronavirus
The purpose of this report is twofold: to identify and discuss a set of challenges, and to develop key recommendations. The overarching goal is to provide support to policymakers in the region who may face difficult decisions to ensure that banks play a constructive role and support families and firms through and beyond the current crisis.
The global public health response to COVID-19 is pivoting from high-income European countries to MICs predominantly in Asia and South America. Effective test, trace, and isolate systems may be particularly valuable in MICs, where social and economic circumstances do not support large and long-term lockdowns. But investing in such systems in MICs comes with a number of limitations and opportunity costs.
In this note, we review Colombia's handling of the COVID-19 crisis. The first line of policy response slowed down the pace of contagion and avoided excess deaths, providing additional time to strengthen the health system and increase ICU capacity. However, the challenges that remain are significant. We provide some policy recommendations for the next stages of the pandemic.
On July 23, 2020, CGD Senior Fellow Prashant Yadav appeared before the House Ways and Means Subcommittee on Trade at a hearing titled “Trade, Manufacturing, and Critical Supply Chains: Lessons From COVID-19.” Yadav’s testimony noted the vulnerabilities in supply chains for medical products clearly exposed by the COVID-19 pandemic and outlined key considerations for US policy toward medical supply chains moving forward.
The COVID-19 pandemic represents a massive global shock that hit Latin America particularly hard.
The sizeable economic and health consequences of COVID-19 are clear as the pandemic spreads, translating into additional burden on health systems not just now but for years to come.
Refugees living in low- and middle-income countries are especially vulnerable to the economic impacts of the COVID-19 pandemic. Based on data from eight hosting countries before COVID-19, we find that refugees are 60 percent more likely than host populations to be working in highly impacted sectors, such as accommodation and food services, manufacturing, and retail.
Substantial evidence has emerged relating to the potential magnitude of the indirect health effects of the coronavirus pandemic.This paper provides an overview of the lessons learned from previous outbreaks and economic crises in relation to indirect health effects as well as a framework for adopting a whole of health approach to the COVID response.
In this policy note, we highlight Pakistan’s Ehsaas Emergency Cash program as a case study, as well as several other examples of cash transfer programs mobilized by governments in light of COVID-19, to reflect how this sort of preliminary analysis can be done.
On June 30, 2020, CGD senior policy fellow Jeremy Konyndyk testified before the Senate Foreign Relations Committee at a hearing titled "COVID-19 and U.S. International Pandemic Preparedness, Prevention, and Response: Additional Perspectives." Konyndyk's testimony highlighted key elements needed for an effective US approach to pandemic preparedness and response and examined the role of the critical role played by the World Health Organization in responding to global health crises.
In this note, we review rigorous studies that have analyzed how COVID-19 and related policies are impacting rates of VAW/C and highlight more reliable methods, while acknowledging limitations of underlying data sources. We propose recommendations for how to both broaden and deepen our collective understanding of how COVID-19 is impacting these forms of violence, and what can be done in response.
Community health workers (CHWs) are often the first point of care for vulnerable and underserved populations in low- and middle-income countries, but do they have the PPE they need to do their jobs?
Early reports suggest the fatality rate from COVID-19 varies greatly across countries, but it's impossible to directly estimate the infection fatality rate in many low- and middle-income countries. To fill this gap, we estimate the adjustments required to extrapolate estimates of the IFR from high- to lower-income regions.
Diagnostic testing is at the center of the policy debate around COVID-19 interventions in India. As of June 1, 2020, India had conducted approximately 3.8 million tests since it began testing in February, but many experts have noted that testing capacity is still drastically insufficient for the needs of the population.
The global impact of the COVID-19 pandemic on economic output and public finances in 2020 and beyond is projected to be massive. Fiscal policy can have a crucial role in mitigating the pandemic’s overall economic impact and promoting a quick recovery. It can help save lives and shield the most-affected segments of population.
Migrant Workers in the Tourism Industry: How has COVID-19 Affected Them, and What Does the Future Hold?
Governments around the world have closed borders and businesses to combat the spread of COVID-19. These measures have had a devastating effect on the tourism industry, cutting travel by 25 percent and costing more than 100 million jobs.
Leave No One Behind: Using a Benefit-Based Advance Market Commitment to Incentivise Development and Global Supply of COVID-19 Vaccines
The global effort to control the COVID-19 pandemic has seen an exceptional allocation of public and philanthropic funds to advance the development of diagnostics, therapeutics, and vaccines as quickly as possible. While critical, even these significant commitments represent only a “down payment” on a price tag that could eventually exceed $50 billion just to scale the production of vaccines to control this global pandemic—amounts that cannot be raised through traditional donor and philanthropic commitments.